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Background
Clinical trials have shown that dendritic cell (DC)-based
vaccines can induce antigen-specific immune responses as
well as clinical responses in patients with stage IV cancer.
In this study, a monocyte-derived DC vaccine pulsed with
HIV antigen lipopeptides (LIPO5) was developed in prep-
aration for a pilot vaccine clinical trial (DALIA) aimed at
boosting the cellular immune response in chronic HIV
infected patients on highly-active antiretroviral therapy
(HAART).
Methods
Monocytes from six HIV-positive subjects on HAART were
cultured with granulocyte macrophage-colony stimulat-
ing factor and interferon-α, loaded with LIPO5 peptides,
and activated with lipopolysaccharide. LIPO5 is com-
posed of five long immunogenic peptides of Gag p17
(17–35), Gag p24 (253–284), Nef (66–97), Nef (116–
145), and Pol (325–355), which are covalently linked to
a palmitoyl-lysylamide chain. DC vaccine development
focused on establishing the method for monocyte isola-
tion and establishing Quality Control (QC) release and
characterization assays to assess the final vaccine product.
Results
We found that monocytes from HIV-positive subjects can
be isolated by elutriation. LIPO5-loaded DC vaccines cul-
tured from the isolated monocytes expressed 61.5 +
27.7% of CD14+, 94.0 + 3.6% of HLA-DR+/CD11c+, 94.8
+ 2.5% of CD80+, 74.2 + 23.5% of CD83+, and 28.5 +
14.9% of Langerin. There was a strong proliferative
response in allogeneic T cells cocultured with the LIPO5-
loaded DC vaccine, as seen in a mixed lymphocyte reac-
tion assay. Furthermore, the vaccine was able to elicit an
HIV antigen-specific response by autologous T cells, as
measured by intracellular IFN-γ staining. At least one pep-
tide epitope response was induced per subject, in which
the majority of the responses were CD8+ T cells and one
was a CD4+ T cell response.
Conclusion
Collectively, these results paved the way for conducting a
pilot DC vaccine clinical trial in HIV patients on HAART
(BB-IND 13748).
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